Cart
sales@molnova.com
N-desmethyl Enzalutamide
CAS No. 1242137-16-1
N-desmethyl Enzalutamide( N-desmethyl MDV3100 | N-desmethyl MDV 3100 | N-desmethyl MDV-3100 )
Catalog No. M10977 CAS No. 1242137-16-1
Amajor metabolite of Enzalutamide (MDV3100) which is an androgen-receptor (AR) antagonist for treatment of prostate cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 50 | In Stock |
|
| 2MG | 28 | In Stock |
|
| 5MG | 46 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 133 | In Stock |
|
| 50MG | 250 | In Stock |
|
| 100MG | 367 | In Stock |
|
| 200MG | 520 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameN-desmethyl Enzalutamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionAmajor metabolite of Enzalutamide (MDV3100) which is an androgen-receptor (AR) antagonist for treatment of prostate cancer.
-
DescriptionAmajor metabolite of Enzalutamide (MDV3100) which is an androgen-receptor (AR) antagonist for treatment of prostate cancer.
-
In Vitro——
-
In Vivo——
-
SynonymsN-desmethyl MDV3100 | N-desmethyl MDV 3100 | N-desmethyl MDV-3100
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor (AR)
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1242137-16-1
-
Formula Weight450.4094
-
Molecular FormulaC20H14F4N4O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 48 mg/mL
-
SMILESCC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)N)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
-
Chemical NameBenzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tran C, et al. Science. 2009 May 8;324(5928):787-90.
2. Richards J, et al. Cancer Res. 2012 May 1;72(9):2176-82.
3. Gibbons JA, et al. Clin Pharmacokinet. 2015 Oct;54(10):1043-55.
molnova catalog
related products
-
JNJ63576253
JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
-
ORM-15341
The active main metabolite of ODM-201, a potent wt/mutant androgen receptor (AR) inhibitor.
-
VPC-14228
VPC-14228 is a specific AR-DBD inhibitor that acts by inhibiting both Y594A and Q592A mutants.
